Details
- Start Date: October 2022
- Phase: Phase 2
- Study Type: Interventional
- Insurance: No insurance is needed
- Benefits: Compensation up to $700 for time and travel
Santos Research Center in Tampa is currently enrolling participants for clinical trials related to respiratory syncytial virus (RSV) - a common respiratory infection that spreads easily during the winter months.
These studies explore investigational vaccines, monoclonal antibodies, and other therapies designed to improve the prevention and treatment of respiratory tract infections.
Enroll Now
Over 400 clinical trials completed - trusted by Tampa Bay patients and major pharmaceutical sponsors.
According to the Centers for Disease Control and Prevention (CDC), RSV infections typically rise between November and February in Florida, making this the peak season for vaccine research and clinical participation.
Respiratory syncytial virus or RSV is a common infection that affects the respiratory tract. RSV usually causes mild cold-like symptoms, but the virus can cause severe breathing problems.
Study-related phone and in-clinic visits with Physician at no cost
Get access to new treatments by participating
RSV clinical trials play a key role in improving vaccine efficacy, antibody strength, and respiratory tract treatment options. Many studies test single-dose or booster-dose vaccines, new injection methods, and compare dose levels to measure immune response.
Participation helps researchers refine seasonal immunization strategies and monitor immune system response across different age groups. Major research partners, including Pfizer and Moderna, are advancing vaccine technology through mRNA and monoclonal antibody platforms such as nirsevimab.
All studies are reviewed by an Institutional Review Board (IRB) and monitored by a data monitoring committee for safety, immune response, and possible adverse events.
If you're interested in other active studies, explore our Tampa Alzheimer's research study currently enrolling participants.
Our team will ask questions about your medical history, current respiratory symptoms, and RSV test results.
You'll meet with a study physician, complete the informed consent process, and undergo a medical evaluation to confirm eligibility.
If you qualify, you may receive a vaccine or placebo injection. Our clinical staff will monitor your progress, tracking antibody levels, reactogenicity, and any adverse events such as mild fatigue, fever, or soreness at the injection site.
Each step is conducted under FDA and IRB supervision to ensure safety and data accuracy.
Each study is reviewed by an independent data monitoring committee and conducted under FDA safety guidelines. Investigators continuously track immunogenicity, dose response, and any serious adverse events to maintain the highest standards of participant safety.
All studies at Santos Research Center are led by qualified Principal Investigators and conducted under FDA-registered, IRB-approved protocols that follow Good Clinical Practice (GCP) standards.
This page provides general information about ongoing clinical research. It is not medical advice. Study participation is voluntary and subject to eligibility criteria.
Get access to new treatments by participating
Ongoing clinical trials study how different treatments, including investigational antibody therapies and vaccines, improve immunization effectiveness and reduce disease incidence.
Many studies also evaluate antigen response and immunogenicity to understand how the body builds protection against infection.
Patients trust Santos Research Center for our compassionate care, professional staff, and clean, welcoming environment.
"The best research center in Tampa - professional, attentive, and always available to answer questions."
Milena G."Very professional. The coordinators and doctors treat you like family."
Reinaldo S."Excellent service, great transportation, and a very clean clinic."
Maria S.Our bilingual team conducts every study under FDA-approved, IRB-reviewed protocols, prioritizing your safety, privacy, and comfort.
RSV symptoms often begin like a mild cold - including cough, runny nose, sore throat, fever, and fatigue.
In infants, seniors, or people with chronic heart or lung disease, the virus can progress to a respiratory tract infection with wheezing or shortness of breath. Seek medical care if symptoms worsen.
To evaluate vaccine efficacy and antibody response in preventing lower respiratory tract infections.
Yes. Pfizer's Abrysvo and Moderna's mResvia are FDA-approved for adults 60 and older. Ongoing trials test booster responses and protection for younger adults and infants.
Infants, seniors, and those with asthma, COPD, or heart disease have the highest risk for severe symptoms or hospitalization.
RSV primarily affects the lower airways, while influenza impacts the entire body. RSV is especially dangerous for infants and older adults during the winter respiratory season.
Yes. All studies are FDA-regulated, IRB-approved, and continuously monitored by a data monitoring committee. Some participants may experience mild short-term reactions like fatigue or soreness.
Your medical information is shared only with authorized research personnel and handled in full compliance with HIPAA and federal research guidelines.
Learn more at the CDC's RSV Vaccine Overview.
Help advance respiratory health research while receiving expert, no-cost care at one of Tampa's most trusted clinical research facilities.
If eligible, you may receive compensation for your time and travel as part of your participation.
Join an RSV clinical trial in Tampa and help advance vaccine and immunization research.
Enroll Now